01—Abstract
Summary
Summary of the 8-K filed May 20, 2024. Cited figures are marked; the original filing is the authoritative source.
On May 20, 2024, Exelixis, Inc. announced that it has entered into a Settlement and License Agreement with Cipla Ltd. and Cipla USA, Inc. The agreement resolves two patent litigations Exelixis brought in response to Cipla's Abbreviated New Drug Application seeking approval to market generic versions of CABOMETYX (cabozantinib) tablets in the 20 mg, 40 mg and 60 mg strengths before the expiration of the applicable patents.
Under the terms of the agreement, Exelixis will grant Cipla a license to market generic versions of CABOMETYX in the United States beginning on January 1, 2031, if approved by the U.S. Food and Drug Administration and subject to conditions and exceptions common to agreements of this type. The parties will also terminate all ongoing Hatch-Waxman Act litigation between them regarding CABOMETYX patents pending in the U.S. District Court for the District of Delaware, with the lawsuits to be dismissed after a period of time to allow for review by the Federal Trade Commission.
The agreement is confidential and subject to review by the FTC and the U.S. Department of Justice. The filing includes forward-looking statements about Exelixis' obligations under the agreement, and identifies Exelixis' ability to meet those obligations as a key risk factor.
02—Key points
Key Highlights
- Exelixis entered into a Settlement and License Agreement with Cipla Ltd. and Cipla USA, Inc. on May 20, 2024.
- The agreement resolves two Hatch-Waxman patent litigations over Cipla's ANDA seeking to market generic CABOMETYX (cabozantinib) tablets before patent expiration.
- Exelixis will license Cipla to market generic CABOMETYX in the United States beginning January 1, 2031, if FDA-approved and subject to customary conditions and exceptions.
- All ongoing Hatch-Waxman litigation regarding CABOMETYX patents in the U.S. District Court for the District of Delaware will be terminated.
- The lawsuits will be dismissed after a period of time to allow for FTC review.
- The agreement is confidential and subject to review by the FTC and the U.S. Department of Justice.
- The filing is made under Item 8.01 (Other Events) and contains forward-looking statements, with Exelixis' ability to perform its obligations identified as a key risk.
03—Questions
Frequently Asked Questions
When can Cipla begin marketing generic CABOMETYX in the United States?
Under the agreement, Exelixis will grant Cipla a license to market generic versions of CABOMETYX in the United States beginning on January 1, 2031, if approved by the FDA and subject to conditions and exceptions common to agreements of this type.
What litigation does the settlement resolve?
The settlement resolves two patent litigations Exelixis brought in response to Cipla's Abbreviated New Drug Application seeking approval to market generic CABOMETYX tablets (20 mg, 40 mg and 60 mg) before the applicable patents expire. The parties will also terminate all ongoing Hatch-Waxman Act litigation regarding CABOMETYX patents pending in the U.S. District Court for the District of Delaware.
Are the terms of the settlement public?
No. The filing states that the Agreement is confidential and is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
When will the lawsuits be dismissed?
The filing states that the lawsuits will be dismissed after a period of time to allow for FTC review, without specifying the exact timing.
What risks does the filing identify?
The forward-looking statements identify Exelixis' ability to effect its obligations under the Agreement as a key risk, along with other factors detailed in the Risk Factors sections of its most recent Form 10-K and subsequent Forms 10-Q.
04—Continue